It has been shown that DCs and macrophages in the chordoma microenvironment highly express regulators of PD-L1, such as AXL, TLR3, and CD40, suggesting that our treatment targeting the PD-1/PD-L1 axis in combination with blockade of the above molecules may provide better therapeutic efficacy (99). This evidence concerns the gene CD274 and chordoma.